Predictive biomarkers for non-muscle invasive bladder cancer patients undergoing BCG treatment

Predictive biomarkers for non-muscle invasive bladder cancer patients undergoing BCG treatment

Bibliographic Details
Main Authors:	H. Huang, H. Yu, X. Li, W. Yang, Y. Shao, H. Liu, S. Chen, T. Qin, X. Lin, H. Han-Zhang, L. Zhang, Q. Liu, J. Liu
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320334960

Similar Items

INTRAVESICAL BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
by: K. M. Figurin
Published: (2014-07-01)

INTRAVESICAL BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
by: K. M. Figurin
Published: (2014-07-01)

Nomogram to predict Bacillus Calmette Guerin (BCG) instillation response in pT1 non-muscle invasive bladder cancer
by: P. Zhou, et al.
Published: (2020-07-01)

Specific gene set scores in prognostic prediction of muscle invasive bladder cancer
by: Y. Kan, et al.
Published: (2020-07-01)

Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer
by: Zhu H, et al.
Published: (2019-05-01)

Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer
by: Xiangming Cheng, et al.
Published: (2018-11-01)

Treatment options in non-muscle-invasive bladder cancer after BCG failure
by: Nathan A Brooks, et al.
Published: (2015-01-01)

Upper urinary tract surveillance in patients with high risk non-muscle invasive bladder cancer managed with intravesical BCG
by: H. Baig, et al.
Published: (2020-11-01)

Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?
by: Marco Racioppi, et al.

Genetic and immunologic determinants of intravesical BCG therapy in non-muscle-invasive urothelial bladder cancer
by: Wojciech Krajewski, et al.
Published: (2014-03-01)

Genetic and immunologic determinants of intravesical BCG therapy in non-muscle-invasive urothelial bladder cancer
by: Wojciech Krajewski, et al.
Published: (2014-03-01)

Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non–Muscle-Invasive Bladder Cancer
by: Tuo Deng, et al.
Published: (2017-06-01)

Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer
by: Sawazaki H, et al.
Published: (2021-08-01)

Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer
by: Azharuddin Mohammed, et al.
Published: (2017-12-01)

Definitions of BCG-failure (EAU) vs BCG-unresponsive (FDA) in high-risk non-muscle invasive bladder cancer: A comparison of patient outcome
by: F.C. De Jong, et al.
Published: (2020-07-01)

Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience
by: Vivek Sharma, et al.
Published: (2020-12-01)

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study
by: Niannian Ji, et al.
Published: (2021-03-01)

Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
by: Fumitaka Koga, et al.
Published: (2018-09-01)

Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer
by: Sahyun Pak, et al.
Published: (2021-04-01)

THE VALUE OF URINARY CYTOLOGY AND HYDRONEPHROSIS TO PREDICT MUSCLE INVASIVE BLADDER CANCER
by: ferdi ardiansyah, et al.
Published: (2016-03-01)

Economic impacts of the Bacillus Calmette-Guérin (BCG) therapy shortage and the proposed solutions for patients with non-muscle invasive bladder Cancer in Aseer Province, Saudi Arabia
by: Mishari H M Alshyarba, et al.
Published: (2020-01-01)

Preoperative serum apolipoprotein A-I levels predict long-term survival in non-muscle-invasive bladder cancer patients
by: Shang Z, et al.
Published: (2018-05-01)

Midkine Is a Potential Urinary Biomarker for Non-Invasive Detection of Bladder Cancer with Microscopic Hematuria
by: Lin H, et al.
Published: (2020-01-01)

PD-L1 expression does not predict BCG-failure in a large cohort of high-risk non-muscle invasive bladder cancer patients
by: F.C. De Jong, et al.
Published: (2020-07-01)

An internal cross-linked polymeric nanoparticle with dual sensitivity for combination therapy of muscle-invasive bladder cancer
by: G.C. Zhu, et al.
Published: (2020-07-01)

Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review
by: F. Lozano, et al.
Published: (2020-07-01)

Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non–muscle-invasive bladder cancer patients
by: Bum Sik Tae, et al.
Published: (2017-05-01)

Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise
by: Fadi Darwiche, et al.
Published: (2015-01-01)

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer
by: Andres F. Correa, et al.
Published: (2015-01-01)

Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
by: Wojciech Krajewski, et al.
Published: (2020-10-01)

Prognostic Value of Preoperative Albumin-to-Alkaline Phosphatase Ratio in Patients with Muscle-Invasive Bladder Cancer After Radical Cystectomy
by: Zhao M, et al.
Published: (2020-12-01)

Intravesical bacillus Calmette - Guérin (BCG) in treating non-muscle invasive bladder cancer (NMIBC)- Analysis of adverse effects and effectiveness between two strains of BCG (Danish 1331 and Moscow)
by: V. Agarwal, et al.
Published: (2020-11-01)

Intravesical BCG instillation is strongly associated with a decreased risk of upper tract urothelial carcinoma recurrence as well as intravesical recurrence in elderly male patients with non-muscle invasive bladder cancer
by: H. Ide, et al.
Published: (2020-07-01)

Bladder preserving tetra-modal therapy for octogenarian with localized muscle invasive bladder cancer
by: T. Inamoto, et al.
Published: (2020-07-01)

Pathological T1 substaging corresponds with BCG-failure and improves the current EAU risk stratification for non-muscle invasive bladder cancer patients
by: F.C. De Jong, et al.
Published: (2020-07-01)

Bladder Cancer–Specific Nuclear Matrix Proteins-4 May Be a Potential Biomarker for Non-Muscle-Invasive Bladder Cancer Detection
by: Zhi-Yong Wang, et al.
Published: (2018-01-01)

<i>TERT</i> Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients
by: Rui Batista, et al.
Published: (2020-01-01)

The predictive value of the ratio of the product of neutrophils and hemoglobin to lymphocytes in non-muscular invasive bladder cancer patients with postoperative recurrence
by: Liu, Z., et al.
Published: (2021)

A Novel Biomarker Based on miRNA to Predict the Prognosis of Muscle-Invasive Bladder Urothelial Carcinoma
by: Yueyi Feng, et al.
Published: (2019-01-01)

Predictors of Outcome of Non–Muscle-Invasive and Muscle-Invasive Bladder Cancer
by: Ramy F. Youssef, et al.
Published: (2011-01-01)